Peter Molloy (left) and chairman William Garner founded Race Oncology in 2016 to commercialise Bisantrene. Photo: Attila Csaszar

Race challenges big pharma mindset

For many cancer sufferers, the side effects of traditional chemotherapy treatments can compound an already difficult situation.

Perth-based Race Oncology is hoping Bisantrene, which it believes to be a ‘cleaner chemotherapy’, will deliver on its potential to treat a range of cancers.

Bisantrene was developed in the 1980s by a US pharmaceutical company, but fell between the cracks at pharmaceutical multinationals, after a series of mergers, largely for financial reasons.


(existing subscribers)

The password field is case sensitive.
Request new password

Register for free

Sign up here for free access to 7 articles per month + twice daily business email alerts.

Thanks! This question prevents spammers...
Enter the characters shown in the image.

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 31/10/17

1 year TSR5 year TSR
thRoto-Gro International0%0%
100thSky and Space Global112%40%
301stRace Oncology22%0%
655thPrimary Gold-39%-20%
811thProtean Energy-90%-41%
726 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$17k Bought
$4k Bought
$20k Bought
Total value as at the date of the transaction
Source: Morningstar


218th↓Primary Gold$0
219th-Protean Energy$0
220th↓Race Oncology$0
221st-Roto-Gro International$0
222nd-Sky and Space Global$0
231 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer